ASH 2022 | Pentostatin + cyclophosphamide for patients with SCD undergoing haploidentical transplantation
Courtney Fitzhugh, MD, National Institutes of Health, Bethesda, MD, shares some insights into a novel pre-conditioning regimen being explored for patients with sickle cell disease (SCD) undergoing haploidentical transplantation. Dr Fitzhugh first explains that with previous regimens, a high rejection rate was observed, and then goes on to discuss a study which explored pentostatin and cyclophosphamide pre-conditioning. Results demonstrated that graft rejection was significantly reduced, although further research needs to be conducted to better understand the increased risk of autoimmune complications observed. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
